Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold greater than placebo-controls SAN FRANCISCO, Dec. 7
Ethara: THE ART OF CURATING THE ABU DHABI GRAND PRIX HOSPITALITY EXPERIENCE
ABU DHABI, UAE, Dec. 7, 2024 /PRNewswire/ — The tens of thousands of visitors at this week’s Abu Dhabi Grand Prix will get to enjoy the biggest ever choice of restaurants, stalls, and beverage spots at Yas Marina Circuit to refresh and refuel over race weekend. Over 100 F&B spo
Phase 2 data from the ongoing HIBISCUS study shows promise that investigational etavopivat could reduce the incidence of vaso-occlusive crises in people with sickle cell disease
Data indicated a trend toward reduced incidence of vaso-occlusive crises over 52 weeks and increased hemoglobin response at 24 weeks compared with placebo Results to be confirmed in the phase 3 component of the HIBISCUS trial PLAINSBORO, N.J., Dec. 7, 2024 /PRNewswire/ — Novo Nordisk today ann
Researchers Report New Opportunities to Improve Quality of Life for People with Non-Malignant Blood Disorders
Studies show promising new options to address unmet needs in sickle cell disease and immune thrombocytopenia SAN DIEGO, Dec. 7, 2024 /PRNewswire/ — Researchers report significant progress toward expanding the therapeutic options available for people with non-cancerous blood conditions in five
Blokees’ Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
SHANGHAI, Dec. 7, 2024 /PRNewswire/ — During the two-day 2024 Singapore Comic Con (December 7–8), Blokees unveiled its new Sesame Street collection for the first time globally and showcased an impressive array of figures. Blokees’ showcase at SGCC spans an impressive range of globally
Research Shows How Lifestyle Factors and Diet Affect Hematologic Care
Studies highlight interactions among lifestyle factors, disease development, and response to treatment SAN DIEGO, Dec. 7, 2024 /PRNewswire/ — Five studies presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition reveal new linkages between blood disorders a
New Research from Children’s Hospital of Philadelphia to Transform Standard of Care Across the Globe for Newly Diagnosed Children with B-cell Acute Lymphoblastic Leukemia
Results will be presented at the 66th American Society of Hematology Annual Meeting PHILADELPHIA, Dec. 7, 2024 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) announced the results of a Phase 3 study that demonstrate
Seattle Children’s researchers greatly improve survival for children diagnosed with the most common form of childhood cancer, changing the standard of care
The findings will be presented during a scientific session at the American Society of Hematology Annual Meeting on Dec. 8 SEATTLE, Dec. 7, 2024 /PRNewswire/ — New findings set to be presented by Seattle Children’s Research Institute at the American Society of Hematology (ASH) Annual Mee
BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in
Landmark Clinical Trial Results Offer New Hope for Kids with Acute Lymphoblastic Leukemia (ALL)
Transformative breakthrough in pediatric leukemia made possible by decades of St. Baldrick’s Foundation funding and support. SAN DIEGO, Dec. 7, 2024 /PRNewswire/ — Groundbreaking results from a major clinical trial, supported in part by the St. Baldrick’s Foundation, were unveiled
